Macrocyclic Immunomodulators for PD-1 Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for modulating the PD-1/PD-L1 pathway, primarily relying on antibodies, have limitations such as stability, bioavailability, and toxicity issues, necessitating the development of alternative small molecule inhibitors for effective cancer therapy.
Innovation Solution
Development of novel compounds, represented by Formulas (I) and (II), which are small molecules designed to inhibit the PD-1/PD-L1 pathway, offering potential advantages in oral administration, stability, bioavailability, and therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies are used to block the PD-1 pathway, then immune responses against cancer are promoted, but stability and bioavailability issues arise
Solution Approach 1:
The patent changes the chemical structure from large antibody molecules to small molecule compounds with specific molecular weight ranges (200-800 Da), improving stability and bioavailability while maintaining PD-1 pathway inhibition efficacy through optimized pharmacokinetic parameters
2Reliability
If therapeutic antibodies are used to block the PD-1 pathway, then immune responses against cancer are promoted, but toxicity issues arise
Solution Approach 1:
The patent optimizes the therapeutic index by adjusting molecular properties including molecular weight (200-800 Da), logP values (0.5-4.0), and hydrogen bond donors/acceptors, achieving effective PD-1 pathway inhibition with reduced toxicity compared to antibody therapies
3Ease of operation
If small molecule inhibitors are developed as alternatives to antibodies, then oral administration and bioavailability are improved, but manufacturing complexity increases
Solution Approach 1:
The patent defines specific parameter ranges for small molecule optimization including molecular weight (200-800 Da), logP (0.5-4.0), and hydrogen bonding characteristics, providing a systematic framework that balances oral bioavailability with manufacturability through controlled chemical space exploration
Data Source
AI summary
Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II):including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.